KalVista Pharma (KALV.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Nov4

KalVista Pharma to release FY2025 Q3 earnings on November 11 Pre-Market EST, forecast revenue USD 4.2 M, EPS USD -1.02

00:08

Sep29

KalVista Pharmaceuticals Proposes $110 Million Convertible Senior Notes Offering

20:28

Sep26

KalVista to Present New Data on EKTERLY for HAE at German Allergy Congress

11:00

Sep24

KalVista Pharmaceuticals Announces $110 Million Convertible Debt Offering, Shares Drop 10.3%

20:26

Sep19

KalVista Pharmaceuticals Obtains EU and Swiss Approval for EKTERLY® and Plans for Market Launch

11:00

Sep11

KalVista Pharma released FY2026 Q1 earnings on September 11 Pre-Market EST, actual revenue USD 1.426 M (forecast USD 2.089 M), actual EPS USD -1.1233 (forecast USD -0.955)

13:30

Schedules & Filings

Schedules

Filings

Sep11

Earning Release(EST)

FY2026 Q1 Earning Release (USD) Revenue 1.426 M, Net Income -60.1 M, EPS -1.1233

Jul10

Earning Release(EST)

FY2025 Q4 Earning Release (USD) Net Income -52.23 M, EPS -0.9845

Mar12

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 13.69 M, Net Income -49.48 M, EPS -0.9183

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More